In an adult with known thyroid carcinoma who develops a new facial rash, what are the possible etiologies and recommended evaluation and management?

Facial Rashes in Thyroid Cancer Patients

In an adult with known thyroid carcinoma who develops a new facial rash, the primary etiologies to consider are: (1) cutaneous metastases from the thyroid cancer itself, (2) drug-induced dermatological toxicities from systemic therapies (particularly tyrosine kinase inhibitors), and (3) unrelated dermatological conditions that must be excluded through clinical evaluation and biopsy when indicated.

Primary Diagnostic Considerations

Cutaneous Metastases from Thyroid Cancer

While cutaneous metastases from thyroid carcinoma are exceptionally rare, they represent a critical diagnosis that should not be missed, as they indicate distant metastatic disease with poor prognosis 1, 2.

Key clinical features to identify:

• Slowly growing nodules, erythematous papules, or ulcerative lesions
• Most commonly located on scalp, face, neck, or anterior chest wall
• Flesh-colored subcutaneous nodules of short duration
• May present years after initial thyroid cancer diagnosis (even 8-14 years later) 3, 1

Diagnostic approach:

• Perform skin biopsy immediately of any suspicious facial lesion in a thyroid cancer patient 1, 4
• Immunohistochemistry should include: TTF-1, thyroglobulin (TG), PAX-8, and Ki67 1
• If cutaneous metastases confirmed, evaluate for other distant metastases with chest CT and whole-body imaging 2
• Consider post-therapy I-131 SPECT/CT, as cutaneous metastases may be radioiodine-avid 3

Drug-Induced Dermatological Toxicities

If the patient is receiving systemic therapy for advanced thyroid cancer, drug-related rashes are highly likely.

For patients on tyrosine kinase inhibitors (sorafenib, lenvatinib):

The most common dermatological adverse events include 5, 6:

• Papulopustular (acneiform) rash: 75-90% incidence, typically on face, scalp, upper chest
• Hand-foot syndrome
• Alopecia
• Desquamation and pruritus
• Hypopigmentation (rare but documented with sorafenib) 7

Grading and management algorithm 8:

Grade 1 (rash <10% body surface area):

• Continue TKI therapy
• Topical emollients
• Mild-strength topical steroids once daily
• Oral/topical antihistamines for pruritus

Grade 2 (rash 10-30% BSA):

• Continue TKI with close monitoring
• Moderate-strength topical steroids once daily OR potent steroids twice daily
• Consider dermatology referral and skin biopsy
• Exclude infectious causes

Grade 3 (rash >30% BSA or Grade 2 with substantial symptoms):

• Withhold TKI immediately
• Potent topical steroids
• Systemic corticosteroids: prednisolone 0.5-1 mg/kg daily for 3 days, then taper over 1-2 weeks
• Mandatory dermatology review
• Consider punch biopsy and clinical photography
• May resume TKI only after improvement to Grade 1

Grade 4 (skin sloughing >30% BSA, Stevens-Johnson syndrome, TEN):

• Permanently discontinue TKI
• IV methylprednisolone 1-2 mg/kg
• Urgent dermatology consultation
• Consider ICU admission

Critical Pitfalls to Avoid

1. Do not assume all rashes in thyroid cancer patients are benign or drug-related - cutaneous metastases, though rare, indicate stage IV disease and fundamentally change prognosis 1, 2

2. Do not delay biopsy - any new facial lesion (particularly nodules, papules, or ulcerations) in a thyroid cancer patient warrants tissue diagnosis 1, 4

3. Do not continue full-dose TKI therapy through Grade 3 rash - this leads to treatment discontinuation and potentially life-threatening complications 5, 8

4. Do not overlook the timing - cutaneous metastases can appear many years after initial thyroid cancer treatment, even after apparent remission 3, 1

Recommended Evaluation Algorithm

Step 1: Characterize the rash

• Distribution (localized vs. diffuse)
• Morphology (papules, pustules, nodules, ulceration, hypopigmentation)
• Body surface area involved
• Associated symptoms (pruritus, pain, burning)

Step 2: Review medication history

• Currently on TKI therapy (sorafenib, lenvatinib)? 5
• Recently started immunotherapy? 8
• Other systemic agents?

Step 3: Physical examination

• Examine entire skin surface, not just face
• Palpate for subcutaneous nodules
• Assess for lymphadenopathy
• Check for signs of systemic illness

Step 4: Determine need for biopsy

• Biopsy indicated if: nodular lesions, ulceration, atypical features, no clear drug relationship, or concern for metastasis 1, 4
• Biopsy may be deferred if: classic drug-induced papulopustular rash in patient on TKI with recent initiation

Step 5: If drug-induced rash confirmed

• Grade severity using CTCAE criteria 8
• Implement grade-appropriate management
• Do not use immunosuppressive therapy for TKI-related rashes (unlike immunotherapy-related rashes)

Step 6: If cutaneous metastases confirmed

• Staging evaluation for other distant metastases (chest CT minimum) 2
• Measure serum thyroglobulin
• Consider radioiodine therapy if lesions are iodine-avid 3
• Multidisciplinary discussion regarding systemic therapy options 9, 5

The distinction between these etiologies has profound implications: drug-induced rashes are manageable with dose modifications and topical therapy, while cutaneous metastases represent advanced disease requiring systemic treatment escalation and portend significantly worse prognosis 1, 2.